Search results
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 1 day agoOverall, NBIX's strategic focus on R&D and commercialization efforts underscores its commitment to...
Neurocrine shares target lifted on neurocrine developments By Investing.com
Investing.com· 13 hours agoOn Thursday, H.C. Wainwright adjusted its price target for shares of Neurocrine (NASDAQ:NBIX)...
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks· 2 days agoAlthough the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Intrust Bank NA
ETF DAILY NEWS· 23 hours ago(NASDAQ:NBIX – Free Report) by 18.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,977 ...
Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Zacks· 3 days agoFree Report) will report quarterly earnings of $1.04 per share in its upcoming release, pointing to a year-over-year increase of 231.7%. Over the past 30 days, the consensus EPS estimate for ...
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
Zacks via Yahoo Finance· 2 days agoNeurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for...
NBIX Stock Sees Surge of Approximately 3.94% in Last Five Days – Knox Daily
Knox Daily· 7 days agoHe buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential. We've...
Sarepta Therapeutics Stock Shows Improved Technical Strength
Investor's Business Daily· 3 days agoSee if Sarepta Therapeutics stock can continue to show renewed price strength and clear that...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Headlands Technologies LLC
ETF DAILY NEWS· 4 days ago(NASDAQ:NBIX – Free Report) by 85.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional ...
Oppenheimer Reiterates Outperform Rating for Neurocrine Biosciences (NASDAQ:NBIX)
ETF DAILY NEWS· 7 days agoCitigroup decreased their price target on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on ...